Hennion & Walsh Asset Management’s Vir Biotechnology VIR Stock Holding History

Hennion & Walsh Asset Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35,132	Closed	-$263K	–	912
2024 Q3	$263K	Sell	35,132 -3,690	-10%	-$32.1K	0.01%	776
2024 Q2	$346K	Sell	38,822 -328	-0.8%	-$3.15K	0.02%	693
2024 Q1	$397K	Buy	39,150 +4,917	+14%	+$50.1K	0.02%	627
2023 Q4	$344K	Sell	34,233 -479	-1%	-$4.38K	0.02%	648
2023 Q3	$325K	Buy	34,712 +2,504	+8%	+$35.7K	0.02%	631
2023 Q2	$790K	Buy	32,208 +635	+2%	+$15.9K	0.05%	417
2023 Q1	$735K	Buy	31,573 +5,358	+20%	+$137K	0.05%	425
2022 Q4	$664K	Buy	+26,215	New	+$643K	0.04%	432

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Hennion & Walsh Asset Management's VIR Position: Q4 2024 in Review

Hennion & Walsh Asset Management sold out of Vir Biotechnology (VIR) in Q4 2024, closing a stake of 35,132 shares — an estimated $263K sold.

Hennion & Walsh Asset Management first reported a position in VIR in Q4 2022 and held it in 8 quarters. The position peaked at $790K in Q2 2023. 208 funds tracked by Wall St. Rank hold VIR as of Q4 2024.

Hennion & Walsh Asset Management reported no remaining Vir Biotechnology position as of Q4 2024 after selling out during the quarter.
Hennion & Walsh Asset Management sold 35,132 Vir Biotechnology shares in Q4 2024, an estimated $263K.
Hennion & Walsh Asset Management first reported a position in Vir Biotechnology in Q4 2022 and held it in 8 quarters.
Hennion & Walsh Asset Management's Vir Biotechnology position peaked at $790K in Q2 2023.
208 funds tracked by Wall St. Rank held Vir Biotechnology as of Q4 2024.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2024, filed 15 Jan 2025.